此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression.

2026年5月8日 更新者:Xueqin Wang、Peking University Sixth Hospital

Research on the Therapeutic Effect and Clinical Indicators of XingpiJieyu Formula in the Treatment of Severe Liver Depression and Spleen Deficiency Type Depression Based on Abnormal Mitochondrial Energy Metabolism Pathway

Study Title: Research on the therapeutic effect and clinical indicators of XingpiJieyu formula in the treatment of severe liver depression and spleen deficiency type depression based on abnormal mitochondrial energy metabolism pathway

Purpose of the Study: (1) Application of XPJYF in the treatment of severe MDD patients for 8 weeks, detection of abnormal mitochondrial energy metabolism and biosynthesis, and exploration of biological markers for the therapeutic effect of XPJYF in the treatment of severe MDD with liver depression and spleen deficiency type. (2) Explore the biological indicators for predicting the antidepressant efficacy of XPJYF in the treatment of severe MDD patients and explore new pharmacological pathways for the combination of traditional Chinese and Western medicine in the treatment of MDD.

To evaluate whether adding Xingpi Jieyu Formula (a traditional Chinese herbal granule) to the standard antidepressant escitalopram improves symptoms in people with severe major depressive disorder (MDD) who also have a specific traditional Chinese medicine pattern called "Liver-Stagnation and Spleen-Deficiency."

Study Design:

100 patients with severe MDD (Liver-Stagnation and Spleen-Deficiency pattern) will be randomly assigned to one of two groups: Test group: Escitalopram + Xingpi Jieyu Formula, Control group: Escitalopram + placebo (identical granules with no active ingredient).

An additional 50 healthy volunteers will serve as a comparison group. Treatment duration: 8 weeks. Double-blind design: neither participants nor study doctors know who receives the real herbal formula or the placebo.

Data Collection Timepoints: Baseline (before treatment), Week 2, and Week 8 (end of treatment). At each timepoint, blood samples and clinical information (e.g., mood ratings, symptom scores) will be collected.

Main Measurements: Blood samples will be tested for markers of mitochondrial energy metabolism (using ELISA). Whole genome testing will be performed in 60 patients (from the MDD groups) and in all 30 healthy volunteers.

Inclusion Criteria: ① Outpatient/inpatient, aged 18-60, right-handed. ② The diagnosis of Western medicine meets the diagnostic criteria of DSM-5 for MDD, as well as the diagnostic criteria for depression and liver depression and spleen deficiency in the 2008 Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine issued by the Chinese Society of Traditional Chinese Medicine HAMD-17 score ≥ 18 points, and HAMD-17 item 3 ≤ 2 points

Exclusion Criteria: ① DSM-5, with the exception of MDD, has any current or past diagnosis of Axis I mental disorders (MINI). Or it does not meet the diagnostic criteria for depression and liver depression and spleen deficiency syndrome in the "Diagnosis and Treatment Guidelines for Common Diseases in Traditional Chinese Medicine" issued by the Chinese Society of Traditional Chinese Medicine in 2008. ② Education years<5 years or IQ<90 points. ③ Suicide ideation or suicidal behavior (HAMD-17 item 3>2 points).

Possible Benefits: May offer a new treatment option for patients with severe depression who do not fully respond to standard antidepressants. May help identify blood markers that can predict which patients are most likely to benefit from adding traditional Chinese medicine to their treatment. May improve understanding of how traditional Chinese medicine affects cellular energy metabolism (mitochondria), potentially leading to better treatments for depression.

Risks and Safety: All study medications (escitalopram and Xingpi Jieyu Formula) are already approved for clinical use. Side effects are known and generally mild. Blood draws may cause temporary discomfort or bruising. Participants will be closely monitored by study doctors. If serious side effects occur, the study medication can be stopped and appropriate medical care will be provided. All personal information and test results will be kept confidential.

Study Location and Approval: This study is led by researchers at Peking University Sixth Hospital (and other collaborating centers) and has been approved by the Medical Ethics Committee.

研究概览

研究类型

介入性

注册 (实际的)

150

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100191
        • Peking University Sixth Hospital
      • Beijing、中国
        • Peking University Sixth Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

① Outpatient/inpatient, aged 18-60, right-handed

② The diagnosis of Western medicine meets the diagnostic criteria of DSM-5 for MDD, as well as the diagnostic criteria for depression and liver depression and spleen deficiency in the 2008 Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine issued by the Chinese Society of Traditional Chinese Medicine HAMD-17 score ≥ 18 points, and HAMD-17 item 3 ≤ 2 points

Exclusion criteria:

  • DSM-5, with the exception of MDD, has any current or past diagnosis of Axis I mental disorders (MINI). Or it does not meet the diagnostic criteria for depression and liver depression and spleen deficiency syndrome in the "Diagnosis and Treatment Guidelines for Common Diseases in Traditional Chinese Medicine" issued by the Chinese Society of Traditional Chinese Medicine in 2008 ② Education years<5 years or IQ<90 points ③ Suicide ideation or suicidal behavior (HAMD-17 item 3>2 points)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:XingpiJieyu Formula + Escitalopram
Patients with severe major depressive disorder (Liver-Stagnation and Spleen-Deficiency pattern according to TCM) receive oral escitalopram (10-20 mg/day) combined with XingpiJieyu Formula granules for 8 weeks.

XingpiJieyu Formula (XPJYF): Traditional Chinese medicine herbal granules. Dosage: 1 sachet (approximately 5 g) taken orally with 200 ml warm water after meals, twice daily.

Escitalopram: Selective serotonin reuptake inhibitor (SSRI) tablets. Dosage: 10 mg/day for the first week; after one week, the dose may be increased to 10-20 mg/day based on clinical response and tolerability.

Both medications are taken for 8 weeks.

安慰剂比较:XingpiJieyu Placebo + Escitalopram
Patients with severe major depressive disorder (Liver-Stagnation and Spleen-Deficiency pattern according to TCM) receive oral escitalopram (10-20 mg/day) combined with a matching placebo for 8 weeks.

XingpiJieyu Placebo: Granules identical in appearance, taste, and administration to Xingpi Jieyu Formula but containing no active pharmaceutical ingredients. Dosage: 1 sachet taken orally with 200 ml warm water after meals, twice daily.

Escitalopram: Same as Arm 1 (10-20 mg/day for 8 weeks).

无干预:Healthy Control
Age- and sex-matched healthy volunteers receive no medication. They undergo the same blood sample collection and clinical assessments at baseline.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
SIRT1 and its mRNA in peripheral blood nucleated cells
大体时间:Baseline (week 0), week 2, and week 8
Detection of SIRT1 and its mRNA in peripheral blood nucleated cells (particularly PBMCs) at the end of 8 weeks treatment from baseline and compared with healthy control on baseline to test biological effectiveness of XPJYF and ESC in the treatment of MDD.
Baseline (week 0), week 2, and week 8
Hamilton Depression Rating Scale, 17 items (HAMD-17) total score changes
大体时间:Baseline (week 0), week 2, and week 8
One hundred MDD patients with treatment - efficacy as assessed by HAMD - 17 on baseline, at the end of 2 weeks and 8 weeks.
Baseline (week 0), week 2, and week 8

次要结果测量

结果测量
措施说明
大体时间
TESS for adverse effect rating
大体时间:Week 2 and week 8
TESS assessment was used to evaluate the adverse effects of XPJYF and ESC treatment in 80 patients with MDD at the end of 2 weeks and 8 weeks of treatment, and the difference in total TESS scores between the two MDD groups (40 patients in each group) was compared.
Week 2 and week 8

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年5月23日

初级完成 (实际的)

2026年1月28日

研究完成 (实际的)

2026年1月31日

研究注册日期

首次提交

2026年5月1日

首先提交符合 QC 标准的

2026年5月8日

首次发布 (实际的)

2026年5月15日

研究记录更新

最后更新发布 (实际的)

2026年5月15日

上次提交的符合 QC 标准的更新

2026年5月8日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅